Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Follicular Lymphoma · 1 trial · 1 indication
Area under the concentration-time curve for 131I-tositumomab from time 0 to 120, 0 to 168, and time 0 to infinity hours (extrapolated), after the end of the dosimetric dose infusion. Unit: %ID.h/mL, where %ID/mL is the percentage of the injected dose per milliliter blood. AUC measures how much drug is in the system over time after infusion.
Cmax is the maximum observed 131I-tositumomab concentration from time zero (end of the dosimetric dose infusion) to 7 days after the end of the infusion. Unit: %ID/mL, where %ID/mL is the percentage of the injected dose per milliliter blood. Cmax is the highest drug concentration in the blood after infusion.
The terminal phase half-life of 131 I tositumomab in hours. Half-life measures how long it takes for the concentration of drug in the blood to decrease by half.
Clearance of 131I-tositumomab after intravenous administration. The clearance of a drug measures the rate at which the drug is removed from the body after the dose.
Volume of distribution at steady state of 131I-tositumomab. Volume of distribution measures how much the drug spreads through the body after the dose.
| Arm | Type | Description |
|---|---|---|
| tositumomab and iodine I 131 tositumomab | EXPERIMENTAL | Subjects participating in this study will receive a standard 5 mCi dosimetric dose of fission-derived Iodine I-131 tositumomab, immediately following an infusion of 450 mg of unlabeled tositumomab. Using the dosimetric data from three of the six imaging time points and the subject's weight, a patient-specific activity (mCi) of Iodine I-131 will be calculated to deliver the desired total body dose of radiation (75 cGy). All subjects will then receive an infusion of unlabeled tositumomab (450 mg) immediately followed by an infusion of the subject specific dose of tellurium-derived Iodine I-131 tositumomab (35 mg) to deliver a total body dose (TBD) of 75 cGy. |
| Name | Type | Description |
|---|---|---|
| Follicular Lymphoma | BIOLOGICAL | For subjects with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's |
Inclusion criteria 1. At least 18 years of age 2. A histologically confirmed diagnosis of the following: Follicular lymphoma, Grade 1, 2, or 3 or diffuse large cell lymphoma concurrent with or following the diagnosis of follicular lymphoma (World Health Organization/Revised European-American Ly...
Follicular Lymphoma is a monoclonal antibody being developed by GSK plc for the treatment of follicular lymphoma, a type of non-Hodgkin's lymphoma. It is currently in Phase 1 clinical development as an investigational therapy for this oncology indication.
Follicular Lymphoma is a monoclonal antibody, but its specific molecular target has not been disclosed. The drug is being studied for its potential role in treating follicular lymphoma, a form of non-Hodgkin's lymphoma.
Follicular Lymphoma is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical research to evaluate this monoclonal antibody for the treatment of follicular lymphoma.
Follicular Lymphoma is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, involving 15 patients with follicular lymphoma.
Follicular Lymphoma has been studied in one completed Phase 1 clinical trial, NCT00315731. This trial evaluated the pharmacokinetics, whole body and organ dosimetry, and biodistribution of the drug in patients with previously untreated or relapsed follicular or transformed non-Hodgkin's lymphoma.
Follicular Lymphoma is associated with the drug BEXXAR, which is a brand name for iodine I 131 tositumomab. The clinical trial NCT00315731 specifically studied this fission-derived iodine I 131 tositumomab formulation in patients with follicular lymphoma.